Syros Pharmaceuticals (NASDAQ:SYRS) and CannTrust (OTCMKTS:CNTTF) Critical Comparison

Profitability

This table compares Syros Pharmaceuticals and CannTrust’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Syros Pharmaceuticals	N/A	-3,369.56%	-97.04%
CannTrust	N/A	N/A	N/A

Volatility & Risk

Syros Pharmaceuticals has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. Comparatively, CannTrust has a beta of 4.52, suggesting that its stock price is 352% more volatile than the S&P 500.

Institutional and Insider Ownership

91.5% of Syros Pharmaceuticals shares are held by institutional investors. Comparatively, 0.1% of CannTrust shares are held by institutional investors. 12.3% of Syros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Syros Pharmaceuticals and CannTrust”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syros Pharmaceuticals	$386,000.00	0.03	-$164.57 million	($3.03)	0.00
CannTrust	$15.96 million	0.00	$7.39 million	$0.07	N/A

CannTrust has higher revenue and earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than CannTrust, indicating that it is currently the more affordable of the two stocks.

Summary

CannTrust beats Syros Pharmaceuticals on 7 of the 9 factors compared between the two stocks.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

About CannTrust

CannTrust Holdings Inc. produces and distributes pharmaceutical grade medical cannabis products in Canada. It sells dried cannabis and oil extractions to the client based on the medication document provided by health care practitioner. The company has a partnership with Gold Coast University Hospital. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.